Figure 4: ET-1 alters the subcellular localization of E-cadherin and β-catenin. Cells were incubated either with or without 10nM ET-1 for 96 hours then fixed and stained with anti- E-cadherin or anti-β-catenin antibodies followed by anti-mouse-IgG-Cy3 antibodies. E-cadherin localization is shown for melanocytes either (A) without or (B) with ET-1 incubation and in melanoma cells either (C) without or (D) with ET-1 incubation. β-catenin localization is shown for melanoma cells either (E) without or (F) with ET-1 incubation and in melanocytes either (G) without or (H) with ET-1 incubation. Melanocyte cell morphology is shown by bright field micrographs of cells either (I) without or (J) with ET-1 incubation. Incubation of melanocytes and melanoma cells with secondary antibody alone revealed no background staining.

IN THE CLAIMS

Please amend claims 1, 4, and 5 to read as follows:

1. A method for treating a cancer, comprising administering a compound that is a selective antagonist to an endothelin B receptor.

4. The method of Claim 1, in which the compound is a mimic of Endothelin-1 that binds to the endothelin B receptor.

5. The method of Claim 1 in which the compound is an antisense molecule that blocks translation of a polypeptide that activates the endothelin B receptor.

Please add new Claims 14 and 15.